Objective: The American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal-Fetal Medicine (SMFM) recommend chromosomal microarray analysis (CMA) for prenatal diagnosis in cases with 1 or more fetal structural abnormalities. For patients who elect prenatal diagnosis and have a structurally normal fetus, either microarray or karyotype is recommended. This study evaluates the frequency of clinically significant chromosomal abnormalities (CSCA) that would have been missed if all patients offered the choice between CMA and karyotyping chose karyotyping.
| INTRODUCTION
Chromosomal microarray analysis (CMA) is increasingly being utilized in prenatal diagnosis due to its improved detection rate of clinically significant chromosomal abnormalities (CSCA) compared with karyotyping. High-resolution single nucleotide polymorphism (SNP)-based microarrays can detect a variety of abnormalities, including whole chromosome aneuploidies, unbalanced rearrangements, microdeletions and microduplications, triploidy, uniparental isodisomy, and low-level mosaicism; whereas karyotyping is limited to detecting whole chromosome aneuploidies, large deletions and duplications (≥5-10 Mb), polyploidy, and some balanced chromosomal rearrangements.
Due to the significant differences in resolution and the increased detection rate of chromosomal abnormalities, CMA has been recommended as a first tier test in the pediatric setting for the evaluation of children with developmental delays, intellectual disabilities, multiple congenital abnormalities, or autism spectrum disorders for over a decade. 1, 2 In prenatal diagnosis, CMA has begun to emerge as a favorable alternative to karyotype analysis. Wapner et al reported that following a normal karyotype, CMA identified an additional 6.0% of pregnancies with a CSCA when there was at least 1 major structural ultrasound abnormality, and in an additional 1.7% of pregnancies with standard indications for testing, such as an increased risk due to an abnormal maternal serum screening or advanced maternal age. 3 Following the publication of this data, the American College of Obstetricians and Gynecologists (ACOG) and the Society for
Maternal-Fetal Medicine (SMFM) published joint recommendations regarding the use of microarray analysis in prenatal diagnosis. The
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This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. societies recommended CMA in lieu of karyotyping for patients who wished to proceed with prenatal diagnosis by chorionic villus sampling (CVS) or amniocentesis in the setting of 1 or more structural fetal anomalies identified by ultrasound. For patients who wished to pursue prenatal diagnosis in the setting of a normal fetal ultrasound, the societies recommend offering either CMA or karyotyping. 4 In the years following these recommendations, microarray technology has transitioned to more sensitive SNP-based methods allowing for the detection of triploidy, uniparental isodisomy, and regions of homozygosity, in addition to copy number variations. Significant advances were also made in prenatal screening technologies, specifically, the ability to analyze cell free placental DNA from maternal blood. Therefore, it is important to reassess current trends as well as the utility of these published recommendations.
In this study, we identified and characterized the reason for referral and any additional clinical data provided for all patients undergoing prenatal CMA, and then classified the patients into 2 groups based upon ACOG/SMFM recommendations. The types of results for both groups were characterized as abnormal (a clinically significant chromosomal alteration was identified), normal (no clinically significant chromosomal alterations were identified), or a variant of uncertain significance (VOUS; a chromosomal alteration was identified that is not clearly associated with a known syndrome, but may act as a risk factor). The purpose of this study was to determine the frequency of CSCA in structurally normal fetuses that would not have been detected if they had been evaluated only by karyotyping rather than CMA.
| MATERIALS AND METHODS
We analyzed 3234 consecutive prenatal samples referred for evaluation by CMA over a 3-year period. All samples included in this study were from ongoing pregnancies. The clinical data provided for each case were used to stratify patients into 1 of 2 previously described groups: those that met ACOG guidelines for CMA in lieu of karyotyping versus those that met ACOG guidelines for CMA or karyotyping (see Table 1 ). Each group was further subdivided by CMA results: normal, abnormal, and variant of uncertain significance (VOUS). For the purpose of this study, VOUS likely benign results were included in the normal group and VOUS likely pathogenic results were included in the VOUS group. Abnormal array results were then evaluated to determine detectability by karyotyping, and were classified as "detectable," "possibly/partially detectable," or "not detectable." For cases in which a karyotype was not performed, classification was determined by copy number size, using the standard detection limit of >10 Mb for a standard resolution karyotype analysis.
Abnormalities that were mosaic but >10 Mb were classified as "possibly/partially detectable," because detection by karyotype is dependent upon the level of mosaicism and the possibility of preferential overgrowth of the normal cell line in culture. If there were multiple copy number variants (CNVs) present and not all would be detected by karyotype, the case was classified as "possibly/partially detected."
Mosaic aneuploidies were included in the "detectable" group. What's already known about this topic?
• Current professional guidelines regarding the use of chromosomal microarray analysis (CMA) versus karyotyping in prenatal diagnosis support CMA over karyotype only when fetal structural abnormalities are present.
• Examination of the clinical utility of these guidelines,
given advances in microarray technology and prenatal screening, is largely unaddressed.
What does this study add?
• detected by CMA that would have been missed by karyotyping alone.
It may be worth noting that the above data do reflect an increase in detection over previously reported and comparable data (a 47.1%
increase compared with previous estimates of 1.7%). 3 Bornstein et al recently reported the prevalence of pathogenic CNVs in 1980 high-risk versus low-risk patients who had undergone prenatal diagnosis by CMA. As expected, pathogenic CNVs were much more common in the high-risk group than the low-risk group, but upon stratification of the high-risk group into subgroups based on the presence or absence of a structural fetal abnormality, the authors reported a pathogenic CNV rate of 2.8% for high-risk patients without structural fetal anomalies and 5.9% for high-risk patients with fetal anomalies, which further supports our findings. 8 Another factor to consider is the average gestational age of each group and how that impacts the testing the patient is offered. In our study, the CMA group had a higher average gestational age (21 weeks ± 4 days) compared with the CMA/Karyotype group (17 weeks ± 4 days), likely because many fetal anomalies are not detectable until later in pregnancy. Accordingly, the CMA group included only 8% CVS procedures, while the CMA/Karyotype group included 36% CVS procedures. This marked difference in gestational age/procedure type between the 2 groups raises an interesting point about the current recommendation that CMA be offered in lieu of karyotyping only when a fetal structural abnormality is present. Under the current guidelines, patients who undergo CVS are more likely to fall into the CMA/Karyotype group due to the limited ability to assess fetal anatomy by ultrasound during the first trimester. By the time amniocentesis is performed, a majority of fetal structural abnormalities diagnosable by ultrasound will be apparent, and patients will be more readily triaged to the appropriate group.
Thus, patients who are undergoing CVS are more likely to have CMA-detectable chromosomal abnormalities missed than patients undergoing amniocentesis.
| Clinical considerations of microarray analysis
Since its introduction to prenatal diagnosis, the benefits and limitations of CMA have been widely debated. Both health care providers and patients have expressed hesitation about replacing karyotyping with CMA due to concerns about the possibility of a VOUS result and the cost of CMA compared with karyotyping.
The frequency of encountering a VOUS by CMA has become a primary concern for patients and their providers. Wapner et al 3 reported
a VOUS rate of 3.4% in their landmark study comparing CMA by aCGH to karyotyping. As we have learned more about incompletely penetrant CNVs, the VOUS category has broadened. Previously, if a variant were identified in a parent, it may have been considered a "likely benign" or "familial" variant, which removed it from the VOUS designation. However, it is now recognized that there are a number of recurrent variants that are incompletely penetrant or act as risk factors for specific phenotypes and thus are not appropriately designated as "likely benign." In addition, with the replacement of aCGH with SNPbased microarray, CMA's diagnostic capabilities increased by allowing for the detection of triploidy, molar pregnancies, uniparental isodisomy, copy neutral regions of homozygosity, low level mosaicism, and MCC. In this study, we had an average VOUS rate of~5%, which is consistent with our overall prenatal VOUS rate. Findings associated with uncertainty and/or clinical variability are not new to the practice of prenatal diagnosis, or even to the area of fetal chromosome analysis.
In a study by Richards et al, the authors compared pregnant patients' perception of risk, anxiety, and worry based on a scenario in which they were faced with an uncertain finding on prenatal genetic testing versus a comparable uncertain finding on fetal ultrasound. The authors found no statistically significant differences between the 2 groups with respect to the patients' perceptions of risk or their emotional/psychosocial responses to these scenarios. 9 With proper pre-test counseling to discuss the benefits and limitations of CMA, including detection rates for clinically significant and VOUS results, patients in both high and low risk populations are better able to make informed decisions related to their pregnancy management.
Another decision-making barrier when considering CMA versus karyotyping is cost. Historically, CMA has been widely perceived as being significantly more expensive than karyotyping. For this reason, CMA was considered less cost effective than karyotyping. 10 However, as the diagnostic power of microarray has increased, updated costbenefit approaches have been considered. Recent economic analyses of prenatal diagnosis by CMA versus karyotyping suggest that CMA is more cost effective for pregnancies in which there is a fetal ultrasound anomaly, which is consistent with current recommendations.
11
Such studies have not yet been performed for low/average risk pregnancies, which may factor into ACOG/SMFM's continued position of offering either karyotyping or CMA, rather than offering CMA to all women undergoing prenatal diagnosis, regardless of the indication.
| Limitations
Because our study relies on client-reported clinical data, it is possible that some cases were incorrectly classified into the CMA/karyotype group due to unreported ultrasound abnormalities. In this case, the aneuploidy was also detected by array and was consistent with the fetal anomalies seen, suggesting that the balanced translocation was an incidental finding. Because not every patient in our study had a karyotype performed, it is possible that there were additional cases of balanced rearrangements that were not detected by CMA. Given that the majority of balanced chromosomal rearrangements have no overt clinical consequences (apart from the reproductive risk for having a child with an unbalanced translocation), the fact that microarray cannot detect truly balanced rearrangements is not offset by the gain in clinical diagnostic rate.
| CONCLUSION
In summary, our data demonstrate that a significant number of clinically relevant chromosome abnormalities would be missed if all women who were offered the option of either CMA or karyotyping chose to have only a karyotype performed. Our study reinforces the diagnostic utility of CMA and supports its use in lieu of karyotyping for all women undergoing prenatal diagnostic testing regardless of the presence or absence of a fetal structural abnormality. These data also reaffirm the fact that more universal and uniform acceptance of CMA not only enables detection of submicroscopic chromosomal imbalances but also provides an opportunity for patients to make appropriately informed reproductive decisions after being made aware of possible fetal outcomes, management options and recurrence risks.
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